Peresolimab
Based on 1 publication(s) in Google Scholar
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.62%
- CAS No.: 2411580-63-5
- Masse moléculaire:145.16 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Peresolimab
More
Activité biologique
Human IgG1 kappa
Human
PDCD1/PD-1/CD279
Peresolimab is an agonist for PD-1 that binds to PD-1 receptor and activates PD-1 signaling pathway. Peresolimab inhibits T cell receptor (TCR) signals, inhibits the activation of T cells, thereby reducing inflammation and disease symptoms[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
-
Immobilized PD-1 Protein, Cynomolgus can bind Peresolimab. The EC50 for this effect is 7.388 ng/mL.
Chemical Information
-
CAS No. 2411580-63-5
-
Appearance Liquid
-
Masse moléculaire 145.16 kDa
-
Color Colorless to light yellow
-
SMILES
[Peresolimab]
-
Synonyms
LY-3462817
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureté et documentation
-
Fiche technique (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Tuttle J, et al. Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. Reply. N Engl J Med. 2023 Jul 27;389(4):378-379. [Content Brief]
[2]. Leane CM, et al., PD-1 regulation of pathogenic IL-17-secreting γδ T cells in experimental autoimmune encephalomyelitis. Eur J Immunol. 2024 Oct;54(10):e2451212. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)